Further, patients likely to be nonbenefitting from EGFR TKI therapy had increased tumor-stroma interactions and showed evidence that the crosstalk between tumor cells and fibroblasts was a source of EGFR TKI resistance. The gene discussed is EGFR; the disease is neoplasm.